Title: Methylprednisolone aceponate* in eczema and other inflammatory skin disorders - a clinical update
Abstract: International Journal of Clinical PracticeVolume 60, Issue 1 p. 85-92 Methylprednisolone aceponate* in eczema and other inflammatory skin disorders – a clinical update T. Ruzicka, Corresponding Author T. Ruzicka Department of Dermatology, Heinrich Heine University, Düsseldorf, Germany †Professor Thomas Ruzicka, Department of Dermatology, Heinrich Heine University, Moorenstrasse 5, D-40225, Düsseldorf, Germany Tel.: + 49 2118 117316 Fax: + 49 2118 117316 Email: [email protected]Search for more papers by this author T. Ruzicka, Corresponding Author T. Ruzicka Department of Dermatology, Heinrich Heine University, Düsseldorf, Germany †Professor Thomas Ruzicka, Department of Dermatology, Heinrich Heine University, Moorenstrasse 5, D-40225, Düsseldorf, Germany Tel.: + 49 2118 117316 Fax: + 49 2118 117316 Email: [email protected]Search for more papers by this author First published: 20 December 2005 https://doi.org/10.1111/j.1368-5031.2005.00754.xCitations: 39 Advantan®, Intendis GmbH, Berlin, Germany Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Summary Methylprednisolone aceponate (MPA) has been shown to provide rapid, reliable and highly effective treatment of eczematous disorders, with an efficacy comparable to that of most reference topical corticosteroids. It also has excellent local and systemic tolerability. MPA is effective in the treatment of facial and scalp eczema and sunburn and has shown promising results in the treatment of psoriasis. Its rapid efficacy and lack of undesirable local and/or systemic side effects make MPA particularly suitable for use in children and infants. The wide range of formulations (0.1%) of MPA, including cream, ointment, fatty ointment, milk and solution, enable treatment to be tailored to the individual patient. In addition, MPA has the advantage of once-daily application compared with twice-daily treatment for other topical corticosteroids, thereby improving patient safety and promoting patient compliance but without compromising efficacy. Citing Literature Volume60, Issue1January 2006Pages 85-92 RelatedInformation